Family donor stem cell transplants in children with leukemia or MDS
Tests family donor transplants in children with leukemia or MDS.
Key facts
- Who runs it
- Michael Pulsipher
- Where
- Chicago, Los Angeles, Milwaukee, Nashville, Oakland, Palo Alto, Philadelphia, Salt Lake City, San Diego, San Francisco, and Valhalla, United StatesSee the 11 sites
- Trial code
- Registry title
- KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- Oct 2015
- Planned end
- Dec 2025
- Type of study
- Interventional
- Treatments tested
- CliniMacs TCR alpha-beta-Biotin system
- Record updated
- 4 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people under 22 with high-risk acute lymphoblastic leukemia, acute myeloid leukemia or myelodysplastic syndrome who need a stem cell transplant from a half-matched family donor.
- Age
- Under 22 years (maximum age 21 years).
- Sex
- All sexes can join.
- Disease stage
- High-risk ALL in first remission, ALL in second remission, MDS, high-risk AML, or AML in second or later remission, with a morphologic remission (fewer than 5% blasts) before transplant.
- Earlier treatment
- No earlier stem cell transplant from a donor. No suitable HLA-matched sibling donor, and no suitable matched or single antigen mismatched related or unrelated donor available, or waiting for one is not in the patient's interest.
- Biomarker or test result
- A KIR favorable, half-matched (haploidentical) family donor must be available.
Main reasons for not taking part
- Pregnant or breastfeeding
- HIV, or uncontrolled fungal, bacterial or viral infection
- Active leukemia in the central nervous system or other active disease outside the bone marrow
- Genetic disorders that lead to leukemia, such as Fanconi anemia, Kostmann syndrome or dyskeratosis congenita
- Poor lung, kidney, heart or liver function, or low Karnofsky/Lansky score (below 60 %)
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- 2.3.1 Inclusion Criteria for the Biology (KIR2DL1 Polymorphisms/ALL MRD), Comparative Outcomes, and Cost Effectiveness Trial
- Any patient with ALL, AML, or MDS who is deemed eligible for and undergoes HCT at participating centers who provides consent for the KIR2DL1 polymorphisms, comparative outcomes and cost-effectiveness portion of the trial
- Any ALL patient undergoing allogeneic HCT at participating centers is eligible for the ALL deep sequence MRD portion of the trial
- Patients ineligible for the KIR-favorable haploidentical phase II trial who require T-cell depletion may be treated using TCR αβ+CD3+/CD19+ cell depletion. These patients will be followed descriptively on this portion of the trial. Preparative regimen will be at the discretion of the transplant center, but the options associated with this protocol are recommended; 2.3.2 Inclusion Criteria for the KIR-favorable Haploidentical Phase II trial:
- Age < 22 years
- Disease and disease status:; ALL high-risk in first remission (<5% blasts by morphology pre-transplant) meeting criteria for transplant. Example CR1 indications: induction failure (>5% blasts by morphology on post-induction BM), minimal residual disease greater than or equal to 1% marrow blasts by morphology after induction, minimal residual disease by flow cytometry >0.01% after consolidation, hypodiploidy (<44 chromosomes), persistent or recurrent cytogenetic or molecular evidence of disease during therapy requiring additional therapy after induction to achieve remission (e.g. persistent molecular BCR-ABL positivity); ALL in second remission: B-cell; early (less than or equal to 36 months from initiation of therapy) BM relapse, late BM relapse with MRD >0.1% by flow cytometry after first induction therapy; T-cell or Ph+ with BM relapse at any time; very early (less than 18 months from initiation of therapy) isolated extramedullary relapse (T or B-cell); Myelodysplastic syndrome (MDS): Any 2001 WHO classification subtype (Appendix I). RAEB-2 patients may proceed directly to transplant, but may also receive induction chemotherapy before transplant. Patients with ≥20% morphologic marrow blasts will require induction therapy to reduce morphologic marrow blasts below 5% before transplant; High-risk AML defined as monosomy 5, del 5q, monosomy 7, M6, M7, t(6;9), FLT3-ITD, or patients who have greater than or equal to 25% blasts by morphology after induction, or who do not achieve CR after 2 courses of therapy. Also, patients with ≥ 0.1% MRD or evidence of progressive extramedullary disease after induction chemotherapy; AML in second or subsequent morphologic remission
- Has not received a prior allogeneic hematopoietic stem cell transplant
- Does not have a suitable HLA-matched sibling donor available for stem cell donation
- Does not have a suitable matched or single antigen mismatched related or unrelated donor available at any time (noted by search), or it is in the patient's best interest as judged by the attending to move forward with stem cell transplantation rather than wait for an unrelated donor to become available (refer to subsection 2.5.1 for further details)
- Has a suitable HLA KIR favorable haploidentical matched family member available for stem cell donation
- Karnofsky Index or Lansky Play-Performance Scale ≥ 60 % on pre-transplant evaluation. Karnofsky scores must be used for patients > 16 years of age and Lansky scores for patients < 16 years of age
- Able to give informed consent if > 18 years, or with a legal guardian capable of giving informed consent if < 18 years
- Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as:; Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 50% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen; Renal: Creatinine clearance or radioisotope GFR ³ 70 mL/min/1.73 m2 or a serum creatinine based on age/gender as follows:; Age Maximum Serum Creatinine (mg/dL) Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1 1 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4; ≥ 16 years 1.7 1.4 The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the CDC.45
- Cardiac: Shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA) or ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA), choice of test according to local standard of care
- Hepatic: \SGOT (AST) or SGPT (ALT) < 5 x upper limit of normal (ULN) for age. Conjugated bilirubin < 2.5 mg/dL, unless attributable to Gilbert's Syndrome
Who cannot take part
- Pregnant or lactating females are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants
- Patients with active CNS leukemia or any other active site of extramedullary disease at the time of enrollment are not permitted. Note: Those with prior history of CNS or extramedullary disease, but with no active disease at the time of pre-transplant workup, are eligible
- Patients with HIV or uncontrolled fungal, bacterial or viral infections are excluded. Patients with history of fungal disease during induction therapy may proceed if they have a significant response to antifungal therapy with no or minimal evidence of disease remaining by CT evaluation
- Patients with genetic disorders (generally marrow failure syndromes) prone to secondary AML/ALL with known poor outcome are not eligible (Fanconi Anemia, Kostmann Syndrome, Dyskeratosis Congenita, etc)
Where in United States
- Lurie Children's HospitalChicago, United StatesEnrolling by invitation
- Children's Hospital Los AngelesLos Angeles, United StatesEnrolling by invitation
- Medical College of WisconsinMilwaukee, United StatesEnrolling by invitation
- Vanderbilt University - Monroe Carell Jr. Children's HospitalNashville, United StatesEnrolling by invitation
- Children's Hospital OaklandOakland, United StatesEnrolling by invitation
- Stanford University Medical CenterPalo Alto, United StatesEnrolling by invitation
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation
- University of Utah, Primary Children's HospitalSalt Lake City, United StatesEnrolling by invitation
- Rady Children's HospitalSan Diego, United StatesEnrolling by invitation
- University of California San FranciscoSan Francisco, United StatesEnrolling by invitation
- New York Medical CenterValhalla, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This is a phase II, open-label, non-randomized, prospective study of haploidentical transplantation using KIR-favorable donors for children with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). The relationship of KIR2DL1 polymorphisms to survival in children with these diseases undergoing any approach to allogeneic HCT during the study time frame will also be determined.
The group in the trial
- KIR Favorable TransplantTreatment being tested
To assess in a multi-center setting whether the disease-free survival (DFS) at one-year post-HCT for children with high-risk ALL, AML and MDS can be improved following favorably KIR-mismatched haplo-HCT using a graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells from CliniMacs TCR alpha-beta-Biotin system
Treatment: CliniMacs TCR alpha-beta-Biotin system
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children With ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
- Plain-language title
- Family donor stem cell transplants in children with leukemia or MDSGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 4 May 2025